71/100B264.96
USD
-6.30
(-2.32%)
Market Closed
Last updated: · Delayed 15 min
Fair value263.24Plus+1%154Price 264.96416
Q4 FY2026 · Earnings report
EPS estimate 3.60Revenue estimate 4.53B
Q4 FY2026 · Earnings report
EPS estimate 3.60Revenue estimate 4.53B
If you had invested in IQVIA Holdings ago, it would be worth $3,437 today, against $4,081 in SPY and $6,291 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
71/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength2
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
IQVIA Holdings key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Value stock · 6.1/10Growth 4.5 · Value 6.1
- Day range
- 263.57 – 272.21
- 52-week range
- 154.50 – 284.50
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 43.67B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 31.85
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.57
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 8.32
- EPS growth forecast (FY2026)
- +8.6%
- Volume
- 90,391
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 1.16
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 59.9/100Environment 65 · Social 56 · Governance 58
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib
- Employees
- 94K
- Website
- iqvia.com
- IPO date
- 9 May 2013
IQVIA Holdings earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
3.60 USD
Revenue estimate
4.53B USD
Last quarter · Q3 FY2026
EPS3.34Beat +2.5%Revenue4.43BBeat +1.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 3.60 | — | — | +7.64% | 4.66B | — | — | +5.30% | |
| Q2 FY2027 | 3.44 | — | — | +9.10% | 4.61B | — | — | +5.46% | |
| Q1 FY2027 | 3.16 | — | — | +9.11% | 4.45B | — | — | +7.15% | |
| Q4 FY2026 | 3.60 | — | — | +5.26% | 4.53B | — | — | +3.72% | |
| Q3 FY2026 | 3.26 | 3.34 | +2.45% | +11.33% | 4.37B | 4.43B | +1.44% | +8.00% | |
| Q2 FY2026 | 3.03 | 3.15 | +3.96% | +12.10% | 4.30B | 4.37B | +1.53% | +8.74% | |
| Q1 FY2026 | 2.82 | 2.90 | +2.84% | +7.41% | 4.10B | 4.15B | +1.24% | +8.41% | |
| Q4 FY2025 | 3.40 | 3.42 | +0.59% | +9.62% | 4.24B | 4.36B | +2.93% | +10.26% | |
| Q3 FY2025 | 2.98 | 3.00 | +0.67% | +5.63% | 4.08B | 4.10B | +0.50% | +5.24% | |
| Q2 FY2025 | 2.77 | 2.81 | +1.44% | +6.44% | 3.97B | 4.02B | +1.19% | +5.32% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 15.91 | — | — | +12.35% | 19.71B | — | — | +6.26% |
| FY2027 | 14.16 | — | — | +9.28% | 18.55B | — | — | +6.13% |
| FY2026 | 12.96 | — | — | +8.65% | 17.48B | — | — | +7.15% |
| FY2025 | 11.89 | 11.93 | +0.30% | +7.09% | 16.18B | 16.31B | +0.77% | +5.85% |
| FY2024 | 11.12 | 11.14 | +0.20% | +9.11% | 15.38B | 15.41B | +0.20% | +2.55% |
| FY2023 | 10.19 | 10.21 | +0.21% | +0.39% | 14.91B | 15.03B | +0.76% | +4.27% |
| FY2022 | 10.15 | 10.17 | +0.22% | +12.62% | 14.38B | 14.41B | +0.20% | +3.86% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
IQVIA Holdings analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
291.33 USD
+9.95%
Analysts' 1-year price targets range from 240.00 to 346.00, with an average of 291.33.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
14 ratings
| Buy | 12 | |
| Hold | 2 | |
| Sell | 0 |
12-month price target
| Highest target | 346.00 |
| Average target | 291.33 |
| Lowest target | 240.00 |
| Current price | 264.96 |
IQVIA Holdings valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 31.85
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 20.44
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 2.52
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 6.56
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 16.00
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
43.67B USD
+
Total debt
16.31B USD
−
Cash and short-term investments
2.42B USD
=
Enterprise value
57.56B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
IQVIA Holdings against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Waters, Agilent Technologies, Natera, IDEXX Laboratories, Mettler-Toledo International, and Illumina, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median31.818.570.6
- Gross marginLowest in 5 years33.3%33.3%35.0%Against its peers: 7 of 7Peers' median 60.6%
- Operating marginAbove its median13.4%10.0%14.3%Against its peers: 6 of 7Peers' median 24.5%
- Net marginAt its median8.3%7.0%9.1%Against its peers: 6 of 7Peers' median 19.9%
- Return on equityAt its median20.9%16.0%22.6%Against its peers: 4 of 6Peers' median 25.1%
- Free cash flow marginAt its median12.6%10.0%16.6%Against its peers: 6 of 7Peers' median 19.1%
- Revenue growthAbove its median5.9%2.8%22.1%Against its peers: 5 of 7Peers' median 6.9%
- EPS growthBelow its median4.7%2.7%246.2%Against its peers: 2 of 5Peers' median 3.5%
- Debt to EBITDAHighest in 5 years5.51×4.10×5.51×Against its peers: 6 of 6Peers' median 1.75×
- Current ratioLowest in 5 years0.750.750.91Against its peers: 7 of 7Peers' median 1.85
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
IQVIA Holdings growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 17.31B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 1.39B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 26.46%
- Operating margin
- 12.82%
- Net margin
- 8.05%
Revenue / Net income
Revenue Net income Net margin
IQVIA Holdings revenue breakdown
By product
FY2025
54.5%Research And Development Solutions40.6%Technology And Analytics Solutions4.8%Contract Sales And Medical Solutions
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Research And Development Solutions | 8.90B | 54.5% | +4.3% |
| Technology And Analytics Solutions | 6.63B | 40.6% | +7.6% |
| Contract Sales And Medical Solutions | 788.00M | 4.8% | +9.7% |
By region
FY2025
47.5%Americas31.8%EMEA20.7%Asia Pacific
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Americas | 7.75B | 47.5% | +5.3% |
| EMEA | 5.19B | 31.8% | +5.4% |
| Asia Pacific | 3.38B | 20.7% | +8.0% |
How IQVIA Holdings makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Research And Development Solutions8.90B 54.5%
Technology And Analytics Solutions6.63B 40.6%
Contract Sales And Medical Solutions788.00M 4.8%
Revenue16.31B 100.0%
Cost of revenue10.88B 66.7%
Gross profit5.43B 33.3%
Selling and administration1.99B 12.2%
Other operating expenses1.26B 7.7%
Operating income2.18B 13.4%
Tax252.00M 1.5%
Other expense570.00M 3.5%
Net income1.36B 8.3%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
IQVIA Holdings financial health
- Cash and short-term investments
- 2.42B USD
- Total debt
- 16.31B USD
- Net cash
- -13.89B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 2.08B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 0.83
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 2.45
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 2.29
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
IQVIA Holdings ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 94.02%
- Institutional holders
- 1,123 (+17)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 94.93%
Who owns the shares
Institutions 94.0% Others 6.0%
As of 30 Jun 2026
Shares free to trade
Free float 156.45M shares ·94.9% Closely held 8.35M shares ·5.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q3 2026 | 0 | 9 | 162.27K | 336.09K |
| Q2 2026 | 0 | 0 | 13.37K | 0.00 |
| Q1 2026 | 0 | 0 | 315.99K | 50.58K |
| Q4 2025 | 0 | 8 | 138.27K | 275.18K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Title: IQVIA Holdings
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry,and it serves biopharmaceutical firms, providers, payers, and policymakers.